ZA989365B - Preparation for treating alzheimer's disease - Google Patents

Preparation for treating alzheimer's disease

Info

Publication number
ZA989365B
ZA989365B ZA989365A ZA989365A ZA989365B ZA 989365 B ZA989365 B ZA 989365B ZA 989365 A ZA989365 A ZA 989365A ZA 989365 A ZA989365 A ZA 989365A ZA 989365 B ZA989365 B ZA 989365B
Authority
ZA
South Africa
Prior art keywords
disease
preparation
treating alzheimer
alzheimer
treating
Prior art date
Application number
ZA989365A
Other languages
English (en)
Inventor
David Robert Howlett
Mitchell Davina Elizabeth
Original Assignee
Boehringer Mannheim Pharm Corp
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp, Smithkline Beckman Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of ZA989365B publication Critical patent/ZA989365B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA989365A 1997-10-15 1998-10-14 Preparation for treating alzheimer's disease ZA989365B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15

Publications (1)

Publication Number Publication Date
ZA989365B true ZA989365B (en) 1999-04-15

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA989365A ZA989365B (en) 1997-10-15 1998-10-14 Preparation for treating alzheimer's disease

Country Status (16)

Country Link
US (1) US6358990B1 (ja)
EP (1) EP1024697A4 (ja)
JP (1) JP2001519364A (ja)
KR (1) KR100573352B1 (ja)
CN (1) CN1281334A (ja)
AU (1) AU751526B2 (ja)
BR (1) BR9814075A (ja)
CA (1) CA2305262A1 (ja)
HU (1) HUP0100024A3 (ja)
IL (1) IL135584A (ja)
NO (1) NO20001869L (ja)
NZ (1) NZ504419A (ja)
PL (1) PL339910A1 (ja)
TR (1) TR200001018T2 (ja)
WO (1) WO1999018794A1 (ja)
ZA (1) ZA989365B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
EA008384B1 (ru) * 2002-06-27 2007-04-27 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Фосфатные соли карведилола, их сольваты, композиции и способы лечения гипертензии, застойной сердечной недостаточности или стенокардии
WO2004002472A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
HUE058352T2 (hu) 2008-02-14 2022-07-28 Lilly Co Eli Új képalkotó szerek neurológiai diszfunkció kimutatására
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
US20230381139A1 (en) * 2020-09-17 2023-11-30 Uti Limited Partnership Methods of treating and/or preventing alzheimer’s disease with r-carvedilol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
IL84845A0 (en) * 1986-12-17 1988-06-30 Glaxo Group Ltd Pharmaceutical compositions comprising a certain carbazolone derivative or a salt thereof
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
WO1996034853A1 (en) * 1995-05-01 1996-11-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CZ24197A3 (en) * 1994-07-27 1997-08-13 Sankyo Co Heterocyclic compounds, usable as allosteric efectors in muscarine receptors
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments

Also Published As

Publication number Publication date
JP2001519364A (ja) 2001-10-23
HUP0100024A3 (en) 2002-12-28
KR20010031108A (ko) 2001-04-16
WO1999018794A1 (en) 1999-04-22
IL135584A0 (en) 2001-05-20
KR100573352B1 (ko) 2006-04-25
PL339910A1 (en) 2001-01-15
TR200001018T2 (tr) 2000-08-21
CN1281334A (zh) 2001-01-24
EP1024697A4 (en) 2007-05-02
AU1089799A (en) 1999-05-03
NZ504419A (en) 2002-11-26
EP1024697A1 (en) 2000-08-09
CA2305262A1 (en) 1999-04-22
NO20001869D0 (no) 2000-04-11
IL135584A (en) 2005-12-18
AU751526B2 (en) 2002-08-22
HUP0100024A2 (hu) 2001-07-30
BR9814075A (pt) 2000-09-26
NO20001869L (no) 2000-06-14
US6358990B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
EP1043991A4 (en) TREATMENT OF ALZHEIMER DISEASE
EP0951293A4 (en) METHOD FOR TREATING ALZHEIMER DISEASE
HUP0103838A3 (en) Alzheimer's disease secretase
EP1007048A4 (en) IDENTIFICATION OF AGENTS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
AU7708498A (en) Nematode model for alzheimer's disease
ZA989365B (en) Preparation for treating alzheimer's disease
GB2287970B (en) "Decorative elements for subceilings"
IL119417A0 (en) Drug for Parkinson's disease
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
GB2288196B (en) "Decorative elements for subceilings"
IL121730A0 (en) Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine
HUP0003684A3 (en) Diagnostic test for alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
IL120269A0 (en) 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
EP1181550A4 (en) METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes
GB9814045D0 (en) Alzheimer's disease
GB9922194D0 (en) Compounds for improved treatment of parkinson's disease
ZA986324B (en) Composition for the treatment of immunodeficiency disease
EP1031034A4 (en) METHOD FOR DIAGNOSTICATING ALZHEIMER'S DISEASE